Literature DB >> 2731109

Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. The Swedish MTC Study Group.

U Bergholm1, H O Adami, G Auer, R Bergström, M Bäckdahl, L Grimelius, G Hansson, O Ljungberg, E Wilander.   

Abstract

Complete follow-up for 4 to 27 years was achieved for virtually all 249 patients with medullary thyroid carcinoma (MTC) diagnosed in Sweden in a 23-year period. Tumor specimens from 241 patients were re-examined with regard to calcitonin immunoreactivity, amyloid content, argyrophil reaction, tumor capsule condition, and nuclear DNA content. In univariate analyses, these factors, with the exception of the argyrophil reaction, were strong predictors of survival. There were twofold-to-threefold differences in hazard rate between patients with a high (greater than 50%) and low (less than 10%) frequency of calcitonin-immunoreactive tumor cells, between those with amyloid-containing and amyloid-free tumors, and between those with an intact and a nonintact tumor capsule. Calcitonin immunoreactivity and the amyloid content also provided prognostic information in multivariate analyses that adjusted for all the other factors mentioned above and in the full multivariate model, which in addition considered age, sex, heredity, stage of the disease, tumor size, and treatment. The strong prognostic capacity of the nuclear DNA content found in univariate analyses became considerably weaker when other morphologic characteristics were considered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731109     DOI: 10.1002/1097-0142(19890701)64:1<135::aid-cncr2820640123>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Prognostic factors for sporadic medullary thyroid carcinoma.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Mustafa Boyabatli
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 2.  The study of endocrine tumors by flow and image cytometry.

Authors:  Ingrid Zbieranowski; David Murray
Journal:  Endocr Pathol       Date:  1992-06       Impact factor: 3.943

3.  Nuclear DNA content of medullary thyroid carcinoma in a large family with the MEN-2A syndrome.

Authors:  H R Haak; C J Cornelisse; B M Goslings; G J Fleuren
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

4.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

5.  RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas.

Authors:  A Thiagalingam; A De Bustros; M Borges; R Jasti; D Compton; L Diamond; M Mabry; D W Ball; S B Baylin; B D Nelkin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  [Progress in the diagnosis and therapy of C cell carcinoma of the thyroid gland].

Authors:  A Frilling; P E Goretzki; H D Röher
Journal:  Langenbecks Arch Chir       Date:  1990

8.  Nuclear DNA analysis and prognosis in carcinoma of the thyroid gland. A nationwide study in Iceland on carcinomas diagnosed 1955-1990.

Authors:  J G Jónasson; J Hrafnkelsson
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma.

Authors:  M F Herrera; J A van Heerden; J A Katzmann; L H Weiland; D M Nagorney; D Ilstrup
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

10.  Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection.

Authors:  H Chen; J R Roberts; D W Ball; D W Eisele; S B Baylin; R Udelsman; G B Bulkley
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.